Today's AFR Page 24:-
Biotech Select Fund Chief investment officer Mark Pachacz's second pick is Tissue Therapies (Nanosonics being first pick).
'Tissue Therapies which is developing novel wound-healing technology that should be available in early 2014. "It finally had a decision reversed by European regulators in its favour and should see rapid advance of its product"'
I like the last five words - of which we were all aware anyway, but nice to see written by others.
Enjoy the weekend.
DYOR
Regards................
Add to My Watchlist
What is My Watchlist?